Our immunohistochemistry study of NID2 in TMA confirmed the bioinformatic findings and pointed to the possibility of using NID2 IHC in the identification of higher-grade glioma in the practice of pathology diagnosis. The gene discussed is NID2; the disease is central nervous system cancer.